- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01523041
Comparison of Two Formulations of Biphasic Insulin Aspart 70
February 22, 2017 updated by: Novo Nordisk A/S
A Randomised, Double Blind, Single Centre, Three Period Crossover Trial Testing the Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 and Characterising the Pharmacokinetics of Biphasic Insulin Aspart 50 in Healthy Male Subjects
This trial is conducted in Europe.
The aim of this trial is to compare two formulations of biphasic insulin aspart 70 and characterise the pharmacokinetics of biphasic insulin aspart 50 and biphasic insulin aspart 70 in healthy male subjects.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Each subject participated in three treatment periods, and were randomly assigned to each of the six treatment sequences in varying order
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Leeds, United Kingdom, LS2 9NG
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Caucasian
- Considered generally healthy upon completion of medical history and physical examination as judged by the Investigator
- Body mass index (BMI) between 19-27 kg/m^2
- Fasting plasma glucose between 3.8-6.0 mmol/L
Exclusion Criteria:
- Participation in any other clinical trial involving other investigational products within the last three months
- Clinically significant abnormal haematology or biochemistry screening tests, as judged by the Investigator
- Any serious systemic infectious disease that occurred in the 4 weeks prior to the first dose of test drug
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BIAsp 70 clinical trial formulation
|
A single dose administrated subcutaneously (s.c., under the skin)
|
Experimental: BIAsp 70 final formulation
|
A single dose administrated subcutaneously (s.c., under the skin)
|
Experimental: BIAsp 50 final formulation
|
A single dose administrated subcutaneously (s.c., under the skin)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Area under the insulin aspart curve in the interval from 0-24 hours
|
Secondary Outcome Measures
Outcome Measure |
---|
t½, terminal half-life
|
Cmax, maximum insulin aspart concentration
|
tmax, the time to maximum insulin aspart concentration
|
Cmin, minimum glucose concentration
|
tmin, time to minimum concentration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 3, 1999
Primary Completion (Actual)
November 30, 1999
Study Completion (Actual)
November 30, 1999
Study Registration Dates
First Submitted
January 25, 2012
First Submitted That Met QC Criteria
January 27, 2012
First Posted (Estimate)
February 1, 2012
Study Record Updates
Last Update Posted (Actual)
February 24, 2017
Last Update Submitted That Met QC Criteria
February 22, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BIASP-1144
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on biphasic insulin aspart 70
-
Novo Nordisk A/SCompletedDiabetes | Diabetes Mellitus, Type 1Germany
-
Novo Nordisk A/SCompletedHealthy | DiabetesGermany
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesUnited Kingdom
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesBelgium, Luxembourg
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesJapan
-
Novo Nordisk A/SCompletedDiabetes | Diabetes Mellitus, Type 1Germany
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesIsrael
-
Novo Nordisk A/SCompletedDiabetes | Diabetes Mellitus, Type 1Denmark
-
Novo Nordisk A/SCompletedHealthy | DiabetesGermany
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1United Kingdom, France, Netherlands, Belgium, Ireland